We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » CDER Should Improve Trial Design, Analysis and Conduct: Center Report
CDER Should Improve Trial Design, Analysis and Conduct: Center Report
August 3, 2011
Improved clinical trial design, analysis and conduct should be a main priority for Center for Drug Evaluation and Research (CDER) as it works to improve regulatory science across the center, and new drug approvals specifically, a draft report from an FDA advisory committee says.